WO6®
Anhydrous Topical Gel
A base for elegant topical preparations with prolonged BUDs.

Scientific Publications
Provided by
Evaluation of the Safety and Skin Irritancy of PCCA WO6® Anhydrous Topical Gel in Human Epidermis Model

SUMMARY: PCCA WO6 Anhydrous Topical Gel has been developed for a broad range of topical applications. With water activity below 0.6 (Aw<0.6), this anhydrous base is allowed extended default beyond-use dates (BUDs). The aim of this study was to evaluate the safety and skin irritancy potential of WO6 Anhydrous Topical Gel. An in vitro reconstructed human epidermis model (Epiderm) that contains normal human-derived epidermal keratinocytes was used. The exposure time required for WO6 Anhydrous Topical Gel to reduce tissue viability by 50% (ET-50) was longer than 24 hours. No sign of cell toxicity during 24-hour treatment has been observed. Based on the correlation between in vivo and in vitro irritancy response, WO6 Anhydrous Topical Gel is non-irritant, and is milder than baby shampoo.

Introduction:
WO6 Anhydrous Topical Gel is one of the proprietary bases in PCCA Anhydrous system, and has been developed for topical application [1]. With water activity below 0.6 (Aw<0.6), anhydrous base provides an unfavorable environment for microbial growth, is therefore allowed extended default beyond-use dates (BUDs) without compromising drug delivery capabilities.

Skin irritation is a local toxic response and is defined as reversible damage to skin following the application of a substance for up to 4 hours [2]. To ensure safety and predict toxicity, the potential of a base to induce skin irritation is an important consideration before using to deliver any active pharmaceutical ingredients (APIs). An in vitro reconstructed human epidermis model that contains normal human-derived epidermal keratinocytes has been validated by European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM) for full replacement of the golden standard Draize test to differentiate skin irritants and non-irritants [3,4].

The aim of this study was to evaluate the safety and skin irritancy potential of WO6 Anhydrous Topical Gel using EpiDerm tissue model.

Methodology:
Reconstructed Human Epidermis
The three-dimensional in vitro human EpiDerm system (EPI-200) was purchased from MatTek (Ashland, MA) (Figure 1). Cultures were maintained with supplied culture media according to the manufacturer’s instructions. The EpiDerm tissues were exposed to 100 µL of test base for 1, 4, 17 and 24 hours at 37°C. Each sample was duplicated. Triton X-100 1% solution was used as a positive control. Tissues left not dosed were to serve as a negative control.

Tissue Viability
Tissue viability was determined by measuring the reduction of 3-[4,5-dimethylthiazol-2-yl] 2,5-diphenyltetrazolium bromide (MTT). The tissues were evaluated for their ability to reduce soluble-MTT (yellow) to formazan-MTT (purple). An MTT solution was prepared following the instruction of MatTek MTT-100 kit. At each time point, after the media and dosing solution were removed from all wells of EpiDerm tissue, the MTT solution was added to the basal side of each tissue and the tissues were incubated at 37°C for 3 hours. The purple formazan product was extracted using provided extractant applied to both the apical and basal side of the tissues. Optical density (OD) of samples were measured at 570 nm and reference OD at 650 nm with a plate reader. Tissue viability was calculated from the OD-Viability standard curve.

Results and Discussion:
WO6 Anhydrous Topical Gel was applied and spread on top of EpiDerm. Tissue viability was determined by MTT assay after 1, 4, 17 and 24 hours of application and results are shown in Figure 2.
Tissues exposed to WO6 Anhydrous Topical Gel were not affected by the base after 4 hours exposure, and maintained 100% viability until 17 hours. After 24 hours, there were still 89% tissue cells alive. In contrast, Triton X-100 at 1%, considered as a moderate-to-mild irritant, led to 22% tissue cell death in 4 hours, and merely 3% cells survived Triton X-100 after 24 hours. Tissues treated by WO6 Anhydrous Topical Gel were above the irritation classification threshold of 50% viability at 24-hour time point, suggesting that WO6 Anhydrous Topical Gel is non-irritant. The exposure time required to reduce cell viability by 50% (ET-50) was significantly longer than 24 hours for WO6 Anhydrous Topical Gel, but only 9 hours for 1% Triton X-100 (Figure 2).

The correlation between in vivo and in vitro irritancy response is linked by ET-50 [5]. In our study, 1% Triton X-100 has shown ET-50 of 9 hours, which is consistent with the classification of moderate-to-mild irritancy and ET-50 range of 4 to 12 hours (Figure 3). A substance with ET-50 of 12 to 24 hours has the same irritancy as baby shampoo, which is very mild. If ET-50 is 24 hours, the irritancy is comparable to 10% Tween 20. Therefore, with ET-50 of longer than 24 hours, WO6 Anhydrous Topical Gel is milder than baby shampoo and as non-irritating as 10% Tween 20.

Conclusions:
To ensure safety and predict potential toxicity, skin irritancy is an important consideration for any topical applied product. Due to the infeasibility of in vivo Draize test in most settings, EURL ECVAM has validated and recommended using the EpiDerm tissue model to define irritancy of a product.

Our study has shown no sign of skin toxicity and that WO6 Anhydrous Topical Gel is a non-irritating substance. It is milder than baby shampoo, and is as non-irritating as 10% Tween 20, which is a commonly used surfactant and emulsifier in personal care products. This study provides a safe option to physicians and compounding pharmacists when choosing bases for topical drug delivery with extended BUDs.

Figure 2. EpiDerm tissue viability profile after 24 hours exposure to WO6 Anhydrous Topical Gel and a positive control (1% Triton X-100).

Figure 3. Correlation of in vitro and in vivo irritancy. (Modified based on MatTek protocol).

References:
PCCA USA
9901 S. Wilcrest Drive
Houston, Texas  77099
Phone: 800.331.2498 or 281.933.6948
Fax: 800.874.5760 or 281.933.6627
pccarx.com

PCCA Canada
744 Third Street
London, ON Canada N5V 5J2
Phone: 800.668.9453 or 519.455.0690
Fax: 800.799.4537 or 519.455.0697
pccarx.ca

PCCA Australia
Unit 1, 73 Beauchamp Road
Matraville NSW 2036 Australia
Phone: 02.9316.1500
Fax: 02.9316.7422
pccarx.com.au

PCCA UK
Unit 2 Regents Drive,
Low Prudhoe Industrial Estate
Northumberland, UK NE42 6PX
Phone: 0800.028.4925
Fax: 0800.083.4222
pccarx.co.uk